MA45426A - Procédés, kits, agents et appareils de transduction - Google Patents

Procédés, kits, agents et appareils de transduction

Info

Publication number
MA45426A
MA45426A MA045426A MA45426A MA45426A MA 45426 A MA45426 A MA 45426A MA 045426 A MA045426 A MA 045426A MA 45426 A MA45426 A MA 45426A MA 45426 A MA45426 A MA 45426A
Authority
MA
Morocco
Prior art keywords
kits
agents
transduction processes
transduction
processes
Prior art date
Application number
MA045426A
Other languages
English (en)
Inventor
Keenan Bashour
Semih U Tareen
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of MA45426A publication Critical patent/MA45426A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA045426A 2015-10-22 2016-10-20 Procédés, kits, agents et appareils de transduction MA45426A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245265P 2015-10-22 2015-10-22
US201662305989P 2016-03-09 2016-03-09
US201662369020P 2016-07-29 2016-07-29

Publications (1)

Publication Number Publication Date
MA45426A true MA45426A (fr) 2019-05-01

Family

ID=57471925

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045426A MA45426A (fr) 2015-10-22 2016-10-20 Procédés, kits, agents et appareils de transduction

Country Status (13)

Country Link
US (3) US11248238B2 (fr)
EP (1) EP3365453A2 (fr)
JP (2) JP7195141B2 (fr)
KR (1) KR102946012B1 (fr)
CN (2) CN116875635A (fr)
AU (2) AU2016341527B2 (fr)
BR (1) BR112018008111A2 (fr)
CA (1) CA3002742A1 (fr)
HK (1) HK1258932A1 (fr)
MA (1) MA45426A (fr)
MX (3) MX395154B (fr)
RU (2) RU2761555C2 (fr)
WO (1) WO2017068419A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
WO2020089343A1 (fr) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Procédés de sélection et de stimulation de cellules et appareil associé
EP3880179A2 (fr) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Compositions à base de fusosomes pour l'administration de snc
KR102159737B1 (ko) 2018-12-28 2020-09-24 강원대학교산학협력단 스트렙택틴 접합된 양자점 및 그 제조방법
CN110129370B (zh) * 2019-05-06 2021-07-20 山东昂科诺生物科技有限公司 一种car-t毒性指示细胞的快速构建方法
US20220228101A1 (en) * 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
KR20220035910A (ko) * 2019-06-21 2022-03-22 노쓰 캐롤라이나 스테이트 유니버시티 Car-t 세포의 인시츄 모집, 재프로그래밍 및 방출
KR102865366B1 (ko) * 2019-12-30 2025-09-26 생-고뱅 퍼포먼스 플라스틱스 코포레이션 세포 형질 도입을 위한 컨테이너 및 방법
JP2023519099A (ja) 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
CA3169672A1 (fr) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Compositions de lymphocytes t a recepteur antigenique chimerique dirige contre cd19 et procedes et utilisations associes
CN115989038A (zh) * 2020-04-10 2023-04-18 北卡罗莱纳州立大学 使用材料支架的增强的哺乳动物细胞病毒转导
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN116438296A (zh) * 2020-11-13 2023-07-14 大集有限责任公司 人工病毒呈递细胞
CN117916256A (zh) * 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
CN116286659A (zh) * 2021-10-25 2023-06-23 黄�俊 多聚体在car表达细胞检测和细胞制备中的应用
CN116930489A (zh) * 2022-04-01 2023-10-24 广东菲鹏生物有限公司 层析试纸条、检测试剂盒及方法
WO2024182516A1 (fr) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques
WO2024258866A1 (fr) * 2023-06-12 2024-12-19 Interius Biotherapeutics, Inc. Compositions et procédés pour le traitement de troubles immunologiques
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用

Family Cites Families (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2467434A (en) 1947-05-10 1949-04-19 Air Associates Inc Servomotor and pressure responsive valve therefor
US3539794A (en) 1967-09-12 1970-11-10 American Cyanamid Co Self-contained chemiluminescent lighting device
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5171081A (en) 1992-05-29 1992-12-15 Pita Joe W Chemiluminescent reactive vessel
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
CA2164226C (fr) 1993-06-04 2011-02-08 Carl H. June Methodes pour stimuler de facon selective la proliferation de cellules t
US6033907A (en) 1995-09-29 2000-03-07 Indiana University Foundation Enhanced virus-mediated DNA transfer
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
DK0776339T4 (da) 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5753499A (en) 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
WO1996023879A1 (fr) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Corps agglutinants - multiplicite de proteines capables de lier diverses petites molecules
WO1996024606A1 (fr) 1995-02-09 1996-08-15 University Of Washington Streptavidine a affinite modifiee
WO1997011183A1 (fr) 1995-04-11 1997-03-27 Trustees Of Boston University Proteines mutantes de streptavidine
US5629205A (en) 1995-05-19 1997-05-13 Allelix Biopharmaceuticals Inc. Promoters for gene expression
US6261554B1 (en) * 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
KR100793625B1 (ko) 1995-09-29 2008-01-11 인디아나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 바이러스-매개된 ｄｎａ 전달을 향상시키는 방법에 의해생산된 생존성 세포 집단 및 이를 포함하는 세포 조성물
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU709831B2 (en) 1995-11-13 1999-09-09 Takara Bio Inc. Method for gene transfer into target cells with retrovirus
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US5773224A (en) 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
DK0935607T3 (da) 1996-08-16 2004-12-06 Harvard College Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0961830A1 (fr) 1997-01-29 1999-12-08 Neurosearch A/S VECTEURS D'EXPRESSION ET PROCEDES D'EXPRESSION $i(IN VIVO) DE POLYPEPTIDES THERAPEUTIQUES
CA2283716A1 (fr) 1997-03-14 1998-09-17 Gabriel O. Reznik Streptavidine a aromes multiples
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
BR9908082A (pt) 1998-02-19 2000-10-31 Harvard College Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
WO2000014257A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
MXPA01007820A (es) 1999-02-04 2003-06-19 Technion Res & Dev Foundation Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
EP1048732A1 (fr) 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Procédé de préparation des protéine secretées sous une forme pliée naturelle
EP1669129A1 (fr) 1999-05-14 2006-06-14 Pall Corporation Membrane électriquement chargée
US6849185B1 (en) 1999-05-14 2005-02-01 Pall Corp Charged membrane
DE60027291T2 (de) 1999-05-14 2007-01-18 Pall Corp. Elektrisch geladene membran
ATE458818T1 (de) 1999-06-07 2010-03-15 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
DE60127113T2 (de) 2000-04-25 2007-06-14 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetische peptide
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
US6638728B1 (en) 2000-06-16 2003-10-28 Pierce Biotechnology, Inc. Coated surfaces with high capacity for capturing target molecules
DK1332222T3 (da) 2000-11-03 2009-07-06 Genentech Inc Stofskifteændringer i fermenteringer der udtrykker rekombinante proteiner
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1227321A1 (fr) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Purification fonctionelle de lymphocytes T antigène-spécifiques par marquage réversible aux multimères MHC
WO2002055992A2 (fr) 2001-01-12 2002-07-18 Becton Dickinson Co Proteines de fusion mhc auto-multimerisantes et intrinsequement fluorescentes et complexes formes de ces proteines
GB0102568D0 (en) 2001-02-01 2001-03-21 Magnetic Biosolutions Sweden A Method
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1427744B1 (fr) 2001-08-27 2007-12-26 Genentech, Inc. Systeme d'expression d'anticorps et ensemble
EP1908769A1 (fr) 2001-08-27 2008-04-09 Genentech, Inc. Système d'expression d'anticorps et ensemble
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
US8076452B2 (en) 2002-03-01 2011-12-13 Erdmann Volker A Streptavidin-binding peptide
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US20050271653A1 (en) 2002-04-23 2005-12-08 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
DE50305695D1 (de) 2002-06-24 2006-12-28 Profos Ag Verfahren zum nachweis und zur entfernung von endotoxin
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP1569510B1 (fr) 2002-09-27 2011-11-02 The General Hospital Corporation Dispositif microfluidique pour la separation de cellules et utilisations de ce dispositif
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1641911A2 (fr) 2003-05-02 2006-04-05 Insception Bioscience, Inc. Appareil et procedes pour l'amplification du nombre de cellules sanguines souche
WO2004104185A1 (fr) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation et isolement de lymphocytes t specifiques de l'antigene
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
SI1656455T1 (sl) 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
US20080050795A1 (en) 2003-11-20 2008-02-28 Biosensor Applications Sweden Ab Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture
BRPI0416807A (pt) 2003-11-21 2007-01-09 Dow Global Technologies Inc sistemas de expressão aperfeiçoados com secreção de sistema sec
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
BRPI0507233B8 (pt) 2004-03-11 2021-05-25 Genentech Inc processo para a produção de um polipeptídeo heterólogo em e. coli
EP1766400B1 (fr) 2004-06-03 2009-04-15 Meso Scale Technologies, LLC Methodes destinees a realiser des analyses de sang total
US8865224B2 (en) 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
JP5255841B2 (ja) 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
WO2006058226A2 (fr) 2004-11-24 2006-06-01 The Trustees Of Boston University Streptavidines dimeres modifiees et leurs utilisations
EP3530321A1 (fr) 2004-12-10 2019-08-28 Peter MacCallum Cancer Institute Procédés et compositions d'immunothérapie adoptive
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US20080274091A1 (en) 2005-05-20 2008-11-06 Virxsys Corporation Autologous T Cell Manufacturing Processes
BRPI0616446A2 (pt) * 2005-09-28 2011-06-21 Cytos Biotechnology Ag composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (fr) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation et utilisation de lymphocytes t regulateurs humains
US20070238169A1 (en) 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US20080279866A1 (en) 2006-08-25 2008-11-13 The Brigham And Women's Hospital, Inc. Induction of immunosuppression by inhibition of ATM
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
DK1903115T3 (da) 2006-09-22 2011-05-23 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af antistoffer
EP1903105B1 (fr) 2006-09-22 2010-04-21 Wacker Chemie AG Procédé pour la production de protéines par fermentation
EP1905839B2 (fr) 2006-09-22 2019-07-10 Wacker Chemie AG Procédé de production de protéines fermentative
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
CA2915560A1 (fr) 2006-10-17 2008-04-24 Tomoaki Fujioka Vaccins peptidiques pour des cancers exprimant les polypeptides mphosph1 ou depdc1
CA2668001C (fr) 2006-11-02 2016-05-03 Kyowa Medex Co., Ltd. Methode d'immunodosage d'un composant devant etre mesure dans un echantillon contenant de l'hemoglobine
US20080255004A1 (en) 2006-11-15 2008-10-16 Invitrogen Dynal As Methods of reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
EP2155782A2 (fr) 2007-03-26 2010-02-24 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP2617827A1 (fr) 2007-03-26 2013-07-24 Celexion, LLC Affichage de surface cellulaire, criblage et production de protéines d'intérêt
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009003493A2 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés compilés pour analyser et trier des échantillons
EP2193199B1 (fr) 2007-08-20 2013-11-06 Nextera AS Expression à la surface des phages par l'intermédiaire de pvii
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
EP2520643B8 (fr) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Systèmes de traitement d'échantillons et procédés
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US9090875B2 (en) 2008-01-29 2015-07-28 Fred Hutchinson Cancer Research Center Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
EP2245054B1 (fr) 2008-01-30 2018-11-28 Pieris Pharmaceuticals GmbH Mutéines de lipocaline de larmes ayant une affinité pour le récepteur tyrosine kinase c-met humain et procédés d'obtention de celles-ci
WO2009106073A2 (fr) 2008-02-28 2009-09-03 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010037395A2 (fr) 2008-10-01 2010-04-08 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (fr) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Transduction virale assistée par des billes
DE102009018647A1 (de) 2009-04-23 2010-10-28 Osram Opto Semiconductors Gmbh Strahlungsemittierende Vorrichtung
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
WO2011053971A2 (fr) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Procédé d'amélioration de sensibilité d'analyses à base d'anticorps
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
CN104531734A (zh) 2009-11-17 2015-04-22 詹森生物科技公司 改善的细菌膜蛋白分泌
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
US9891148B2 (en) 2010-02-09 2018-02-13 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9242244B2 (en) 2010-02-09 2016-01-26 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9370732B2 (en) 2013-02-15 2016-06-21 Douglas T. Gjerde Methods for purifying biological cells
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
EP2363501A1 (fr) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Nanocomposites dotés d'une homogénéité améliorée
JP5665021B2 (ja) 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
WO2011130617A2 (fr) 2010-04-15 2011-10-20 Smartflow Technologies, Inc. Bioréacteur intégré et système de séparation et procédés d'utilisation de celui-ci
US9677038B2 (en) 2010-06-23 2017-06-13 Strobbe Pharma Tech Gmbh Device and method for industrial cultivation of cells
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
EP2601521B1 (fr) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification d'antigènes cibles de lymphocytes t
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2012058627A2 (fr) 2010-10-29 2012-05-03 Miqin Zhang Système de nanoparticules préciblées et procédé de marquage de particules biologiques
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012123269A1 (fr) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Compositions immunigènes et procédés pour leur utilisation
WO2012129514A1 (fr) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Méthodes et compositions pour une immunothérapie cellulaire
JP5840857B2 (ja) 2011-04-08 2016-01-06 国立大学法人 東京大学 細胞傷害性ｔ細胞誘導用組成物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
US9353161B2 (en) 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
WO2013062365A2 (fr) 2011-10-26 2013-05-02 국립암센터 Lymphocyte t transfecté par un gène ctla4 mutant et composition en contenant pour immunothérapie anticancéreuse
WO2013071154A1 (fr) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013113615A1 (fr) 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Molécules d'anticorps bispécifiques avec des lymphocytes t transfectés par un antigène et leur utilisation en médecine
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
KR20210149195A (ko) 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP2711418B1 (fr) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Procédé de stimulation polyclonales de lymphocyte T par nanomatrices flexibles
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
EP2920204B1 (fr) * 2012-11-16 2019-09-18 IBA GmbH Mutéines de streptavidine et procédés d'utilisation associés
JP2016504918A (ja) 2013-01-31 2016-02-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ タンパク質を製造する方法
US9920294B2 (en) 2013-02-15 2018-03-20 Douglas T. Gjerde Devices and methods for purification, detection and use of biological cells
US10220332B2 (en) 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
US10107729B2 (en) 2013-02-15 2018-10-23 Douglas T. Gjerde Isolation, detection and use of biological cells
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
WO2015027142A2 (fr) 2013-08-23 2015-02-26 The Scripps Research Institute Accroissement de l'efficacité de la transduction rétrovirale de cellules hôtes
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
NZ759969A (en) * 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP2886645A1 (fr) 2013-12-20 2015-06-24 Julius-Maximilians-Universität Würzburg Expansion de lymphocytes T humains in vitro par des anticorps monoclonaux anti-CD28 classiques liés à une bille
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
CN106456670B (zh) 2014-04-25 2020-01-07 蓝鸟生物公司 制备过继性细胞疗法的改善方法
CN106662584B (zh) 2014-04-30 2020-05-05 Iba股份有限公司 分离靶细胞的方法
EP3172231B1 (fr) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Récepteurs de l'antigène chimérique bcma
CA2956385A1 (fr) * 2014-07-25 2016-01-28 Theravectys Vecteurs lentiviraux pour l'expression regulee d'une molecule recepteur d'antigene chimere
GB201415344D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Protein
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
EP3227323B1 (fr) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Procédés et compositions pour thérapie cellulaire adoptive
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN104696575B (zh) 2015-03-16 2017-06-06 张家港富瑞特种装备股份有限公司 低温管路用电磁阀
EP3274453B1 (fr) 2015-03-26 2021-01-27 Editas Medicine, Inc. Conversion génique via crispr/cas
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
EP3081740A1 (fr) 2015-04-13 2016-10-19 Geoservices Equipements Système et procédé permettant d'échantillonner un fluide de forage sortant d'un puits de forage
WO2016166568A1 (fr) * 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Procédés, kits et appareil permettant d'augmenter une population de cellules
RU2761555C2 (ru) * 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
CN108884460B (zh) 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
WO2018106732A1 (fr) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production de cellules modifiées pour une thérapie cellulaire adoptive
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
US20190247846A1 (en) 2018-02-09 2019-08-15 Chris Suh Method and Apparatus for Pipette Tip Columns
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
WO2020089343A1 (fr) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Procédés de sélection et de stimulation de cellules et appareil associé
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
US20250297282A1 (en) * 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use

Also Published As

Publication number Publication date
AU2016341527A1 (en) 2018-05-10
MX2022010687A (es) 2022-09-26
US20220243223A1 (en) 2022-08-04
MX2018004871A (es) 2018-11-09
JP2023011856A (ja) 2023-01-24
JP2018534928A (ja) 2018-11-29
AU2023206191A1 (en) 2023-10-05
MX395154B (es) 2025-03-25
MX2022010686A (es) 2022-09-26
WO2017068419A3 (fr) 2017-05-26
JP7195141B2 (ja) 2022-12-23
CN116875635A (zh) 2023-10-13
JP7559029B2 (ja) 2024-10-01
US20200017880A1 (en) 2020-01-16
CN108474002A (zh) 2018-08-31
CN108474002B (zh) 2023-05-23
RU2021134624A (ru) 2022-03-15
EP3365453A2 (fr) 2018-08-29
NZ741861A (en) 2024-02-23
KR102946012B1 (ko) 2026-04-01
US12129477B2 (en) 2024-10-29
RU2761555C2 (ru) 2021-12-09
RU2018118574A (ru) 2019-11-25
BR112018008111A2 (pt) 2018-11-06
KR20180108567A (ko) 2018-10-04
WO2017068419A2 (fr) 2017-04-27
CA3002742A1 (fr) 2017-04-27
US20250019723A1 (en) 2025-01-16
US11248238B2 (en) 2022-02-15
AU2016341527B2 (en) 2023-04-27
RU2018118574A3 (fr) 2020-07-28
HK1258932A1 (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
EP3775196A4 (fr) Procédés de génération de nanoréseaux et de microréseaux
IL259837A (en) Microfluidic devices and kits and their uses
MA45488A (fr) Procédés, kits et appareil de culture de cellules
MA45489A (fr) Procédés de culture de cellules, kits et appareil associés
EP3322278A4 (fr) Appareil, systèmes et procédés de distribution de semences
EP3485068A4 (fr) Procédés, dispositifs et compositions électrochimiques
EP3359086A4 (fr) Appareils et procédés à base de cathéter
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
EP3437459A4 (fr) Appareil de greffage
MA50569A (fr) Ensembles de remplissage-finition et procédés associés
EP3615612A4 (fr) Compositions thermoplastiques, procédés, appareil et utilisations
EP3351995A4 (fr) Appareil de visiocasque
EP3602557A4 (fr) Appareils et procédés de désaccentuation de bits partiels
EP3344947A4 (fr) Appareil, systèmes et procédés pour spectromètres de talbot
EP3697682A4 (fr) Procédés et appareil de construction de dirigeables
EP3448516A4 (fr) Appareils et procédés de photothérapie
EP3504217A4 (fr) Procédés de couplage croisé
EP3727179A4 (fr) Procédés et appareil de désinfection
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3426262A4 (fr) Agents de réticulation et procédés associés
EP3311878A4 (fr) Appareil de serrage
MA46927A (fr) Procédés de détection du cancer
MA46865A (fr) Compositions de caryophyllène, appareils et procédés
EP3576851A4 (fr) Dispositif pour multiples doigts destiné à des exercices manuels
EP3308467A4 (fr) Appareils et procédés permettant de fournir des tensions de référence